Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Pharma, Inc. filings document a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, including financial results, product revenue disclosures, program updates, and formal reports on ATTR-CM, LGMD2I/R9, and achondroplasia development programs.
Its SEC record includes Form 8-K disclosures for results of operations, Regulation FD presentations, clinical and regulatory press releases, material agreements, an at-the-market equity distribution agreement, convertible senior notes, and a board-authorized stock repurchase program. Proxy materials address director elections, executive compensation votes, auditor ratification, incentive plan share reserves, governance structure, and stockholder voting matters.
BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for encaleret as a targeted treatment for autosomal dominant hypocalcemia type 1 (ADH1). In the Phase 3 CALIBRATE trial, encaleret met all pre-specified primary and key secondary efficacy endpoints.
At Week 24, 76% of participants on encaleret achieved both serum and urine calcium within target ranges, compared with 4% on conventional therapy at Week 4 (p<0.0001). The company states that encaleret may be eligible for priority review and that it anticipates a potential U.S. launch in early 2027, if approved.
BridgeBio plans additional regulatory and development steps, including a Marketing Authorization Application to the EMA for ADH1 in the second half of 2026, ongoing enrollment of the CALIBRATE-PEDS pediatric ADH1 study, and initiation of the -HP Phase 3 study in chronic hypoparathyroidism in Summer 2026. Encaleret has Fast Track and Orphan Drug designations in multiple regions.
BridgeBio Pharma, Inc. CEO Neil Kumar reported insider sales executed through family trusts. Trusts associated with him sold a total of 80,000 shares of common stock in open-market transactions on May 7–8, 2026, at weighted average prices generally between about $66 and $69 per share, under a pre-arranged Rule 10b5-1 sales plan adopted on March 31, 2025. The sales were made by the Kumar Haldea Revocable Trust and the Kumar Haldea Family Irrevocable Trust, where he serves as co-trustee and disclaims beneficial ownership beyond any pecuniary interest. After these transactions, Kumar still holds 234,451 shares of common stock directly as of May 7, 2026, in addition to substantial indirect trust holdings.
BridgeBio Pharma, Inc. entered into a new Equity Distribution Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC to establish an at-the-market stock offering program. The company may sell, at its discretion, shares of common stock with an aggregate offering price of up to $500,000,000 through these sales agents on Nasdaq or other existing markets.
The sales agents will use commercially reasonable efforts on a best efforts basis, and BridgeBio will pay them a commission of up to 3.0% of gross proceeds on any shares sold. In connection with the new arrangement, BridgeBio and the agents agreed to terminate their prior Equity Distribution Agreement dated May 4, 2023, effective May 7, 2026.
BridgeBio Pharma filed a shelf registration and prospectus supplement to offer up to $500,000,000 of its common stock under an equity distribution agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC. Shares may be sold from time to time in at-the-market transactions, block trades or negotiated sales.
The prospectus highlights that on May 6, 2026 the closing price was $68.09 per share and provides an illustrative share count assuming sales of 7,343,222 shares. Use of proceeds is for general corporate purposes, including R&D, commercialization of Attruby, working capital and potential investments.
BridgeBio Pharma, Inc. reported net revenues of $194.5 million for the three months ended March 31, 2026, up from strong growth in Attruby and Beyonttra sales, including $180.6 million of net product revenue.
The company recorded a net loss attributable to common stockholders of $164.0 million, or $0.84 per share, as it continues to invest heavily in research and development and selling, general and administrative activities. Operating cash outflow was $197.3 million, but BridgeBio ended the quarter with $879.9 million in cash and cash equivalents and $60.3 million in marketable securities.
BridgeBio issued $632.5 million of 0.75% Convertible Senior Notes due 2033, using part of the proceeds to repurchase common stock and positioning itself to address existing convertible notes. The company also submitted a New Drug Application for oral BBP-418 for LGMD2I/R9 and continues late-stage development of low-dose infigratinib and encaleret.
BridgeBio Pharma reported strong first-quarter 2026 growth while remaining unprofitable and launched a major buyback. Total revenue reached $194.5 million, up from $116.6 million a year earlier, driven by $180.6 million in U.S. Attruby net product revenue and higher royalties from BEYONTTRA in Europe and Japan.
Total operating costs and expenses rose to $300.5 million as the company invested in Attruby commercialization and late-stage pipeline programs, leading to a net loss of $166.6 million, or $0.84 per share, similar to the prior year. Cash, cash equivalents, and marketable securities were $940.2 million as of March 31, 2026, bolstered by new convertible note financing.
The board approved a stock repurchase program of up to $500 million of common stock, which can be executed over time at management’s discretion. BridgeBio highlighted real-world and clinical data supporting Attruby, reported an NDA submission for BBP‑418 in LGMD2I/R9, and outlined plans to file NDAs for encaleret and oral infigratinib in 2026, positioning three programs for potential launches in 2026–2027.
BridgeBio Pharma’s Chief Accounting Officer, Apuli Maricel, sold shares under a pre-set trading plan. On April 30, 2026, Maricel executed an open-market sale of 2,000 shares of Common Stock at $71.58 per share. After this transaction, Maricel directly holds 134,115 shares. The sale was made pursuant to a Rule 10b5-1 sales plan adopted on September 8, 2025, indicating it was pre-arranged rather than timed spontaneously.
BridgeBio Pharma, Inc. will hold its 2026 annual stockholders meeting virtually on June 22, 2026, to vote on key governance and compensation items. Stockholders of record at the close of business on April 23, 2026, when 195,806,242 common shares were outstanding, may vote.
Proposals include electing three Class I directors, advisory votes on executive pay and the frequency of future say‑on‑pay votes, ratifying Deloitte & Touche LLP as auditor for 2026, and approving an amendment to the 2021 Stock Option and Incentive Plan to add 2,000,000 reserved shares. Director Randal W. Scott will not stand for re‑election, and the board size will be reduced from 14 to 13.
The company highlights a pay‑for‑performance philosophy: in 2025, 93% of CEO pay and 88% of CFO pay were at risk via bonuses and equity, and performance stock units and a stock ownership policy were added after prior say‑on‑pay support of about 75% and investor feedback.
BridgeBio Pharma reports beneficial ownership by Neil Kumar of 9,282,982 shares of Common Stock. That ownership represents 4.6% of the class based on 195,707,702 shares outstanding as of March 31, 2026. The filing breaks the total into direct holdings, exercisable options, restricted stock units vesting within 60 days, and shares held in trusts.
The filing lists 3,903,183 options exercisable within 60 days and 71,215 RSUs vesting within 60 days, plus trust-held shares totaling 5,074,133 that give shared voting/dispositive power.